Harper Meds vs Pallas Health
A four-week fill against twelve-week billing, which are two different calendars.
Harper Meds
Editorial
$161/mo
Harper Meds prices compounded semaglutide at a flat $149 and compounded tirzepatide at a flat $196, with the consultation, the prescription, four weeks of medication and free shipping inside the charge. Both rates are stated as flat at every dose. Four weeks is not a calendar month, so thirteen fills land in a year and the figures ranked here are $161 and $212.
Pick it for: Readers who want the shorter commitment between charges
Pallas Health
Editorial
$216/mo
Pallas Health charges $139 for a first month of compounded semaglutide and $597 every twelve weeks after it, which the seller averages to $199 a month. Twelve weeks is 2.76 calendar months rather than three, so the figure ranked here is $216, and the $897 tirzepatide block works out at $325. Provider care and check-ins are described as included, and the rate is stated as the same at every dose.
Pick it for: Readers who would rather pay once a quarter than once a month
Our verdict
Harper Meds bills all-inclusive on a four-week fill; Pallas Health bills every twelve weeks. Neither interval is a calendar month, so neither headline is a monthly cost without arithmetic.
What actually separates them
Harper Meds and Pallas Health state different things about published price. Everything else they publish, they publish the same way.
Pallas Health costs $55 more than Harper Meds — 34% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,932 at Harper Meds against $2,592 at Pallas Health — a difference of $660.
| Harper Meds | Pallas Health | |
|---|---|---|
| Published price | $161/mo | $216/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.